Literature DB >> 30374426

European Thyroid Association (ETA) and Thyroid Federation International (TFI) Joint Position Statement on the Interchangeability of Levothyroxine Products in EU Countries.

Eric Fliers1, Barbara Demeneix2, Ashok Bhaseen3, Thomas H Brix4.   

Abstract

Several European countries have seen major health issues after a switch from one levothyroxine brand to another, as well as following the introduction of several levothyroxine formulation changes. While the relationship between these health issues and brand or formulation changes merits further investigation, the current position statement on behalf of both health-care providers and patients summarizes recent events in several European countries and provides a number of recommendations to limit the burden for patients, so as to prevent increased health-care consumption and health-care expenses in this context.

Entities:  

Keywords:  European Thyroid Association; Health issues; Levothyroxine products; Thyroid Federation International

Year:  2018        PMID: 30374426      PMCID: PMC6198781          DOI: 10.1159/000493123

Source DB:  PubMed          Journal:  Eur Thyroid J        ISSN: 2235-0640


  3 in total

1.  Joint statement on the U.S. Food and Drug Administration's decision regarding bioequivalence of levothyroxine sodium.

Authors: 
Journal:  Thyroid       Date:  2004-07       Impact factor: 6.568

2.  Doubling in the use of thyroid hormone replacement therapy in Denmark: association to iodization of salt?

Authors:  Charlotte Cerqueira; Nils Knudsen; Lars Ovesen; Peter Laurberg; Hans Perrild; Lone Banke Rasmussen; Torben Jørgensen
Journal:  Eur J Epidemiol       Date:  2011-06-10       Impact factor: 8.082

3.  New levothyroxine formulation meeting 95-105% specification over the whole shelf-life: results from two pharmacokinetic trials.

Authors:  Ulrike Gottwald-Hostalek; Wolfgang Uhl; Peter Wolna; George J Kahaly
Journal:  Curr Med Res Opin       Date:  2016-10-21       Impact factor: 2.580

  3 in total
  2 in total

Review 1.  Levothyroxine Formulations: Pharmacological and Clinical Implications of Generic Substitution.

Authors:  Salvatore Benvenga; Allan Carlé
Journal:  Adv Ther       Date:  2019-09-04       Impact factor: 3.845

2.  Tea consumption affects the absorption of levothyroxine.

Authors:  Ying-Wen Lai; Shih-Ming Huang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-12       Impact factor: 6.055

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.